Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06278337 |
Other study ID # |
C19-35 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 12, 2021 |
Est. completion date |
January 12, 2027 |
Study information
Verified date |
January 2024 |
Source |
Institut National de la Santé Et de la Recherche Médicale, France |
Contact |
Isabelle ANDRE, Doctor |
Phone |
01 42 75 43 37 |
Email |
isabelle.andre[@]inserm.fr |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is
characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out
of 7 participants had the same missense mutation in the moesin gene located on the X
chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP
codon into the protein.Clinically the 7 participants with X-linked moesin-associated
immunodeficiency all presented with recurrent bacterial infections of the respiratory,
gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the
absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated
with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or
treated with immunoglobulin substitution and/or prophylactic antibiotics.
Since this study, the moesin gene has been integrated into DNA chips used for the molecular
diagnosis of immune deficiencies in several countries. Physicians in Canada, the United
States, Japan, South Africa and Europe have contacted us with a total of 16 known
participants to date. Because of their very low severe, uncontrolled CMV infection and the
absence of treatment recommendations, two 2 American participants were treated with
allogeneic transplantation with severe post-transplant complications (1), and one of the
participants died as a result of the transplant. Management of XMAID participants therefore
varies widely from country to country, depending on age at diagnosis and clinical picture. It
ranges from no treatment treatment (associated with recurrent infections and skin
manifestations), IgIv substitution and/or antibiotic prophylaxis antibiotic prophylaxis, with
low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks
involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection).
The Investigators therefore feel it is important to review the diagnosis, clinical
presentation and management of X-MAID participants. The study the investigator propose will
enable to understand the presentation of X-MAID participants, establish guidelines and
provide the best treatment for each patient according to his or her clinical picture
Description:
Since this study, the moesin gene has been integrated into DNA chips used for the molecular
diagnosis of immune deficiencies in several countries. Physicians in Canada, the United
States, Japan, South Africa and Europe have contacted us with a total of 16 known
participants to date. Because of their very low severe, uncontrolled CMV infection and the
absence of treatment recommendations, two 2 American participants were treated with
allogeneic transplantation with severe post-transplant complications (1), and one of the
participants died as a result of the transplant. Management of XMAID participants therefore
varies widely from country to country, depending on age at diagnosis and clinical picture. It
ranges from no treatment treatment (associated with recurrent infections and skin
manifestations), IgIv substitution and/or antibiotic prophylaxis antibiotic prophylaxis, with
low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks
involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection).
The investigators therefore feel it is important to review the diagnosis, clinical
presentation and management of X-MAID participants. The study the investigators propose will
enable to understand the presentation of X-MAID participants, establish guidelines and
provide the best treatment for each participant according to his or her clinical picture